

Add the following new Claims 29-32.

Claim 29 (new). A compound according to Claim 5 which is selected from

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene; — 16

N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone; — 17

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene; — 18

N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene; — 19

N-Propionyl, N-(2-(3-diethylamino-propyl))-1-amino-4-chloronaphthalene; — 20

N-Propionyl, N-(2-Diethylaminoethyl)-1-4-azidonaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine;

N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine;

N-Propionyl, N-(2-Piperidylethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(N-benzyl)-aminoethyl)-1-aminonaphthalene;

N-(2-Diethylamino-ethyl)-N-(7-methyl-quinolin-4-yl)-propionamide;

N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene; and — cm 22

N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene). — cm 23

Claim 30 (new). A compound according to Claim 1 which is a pharmaceutically acceptable salt.

Claim 31 (new). A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.

Claim 32 (new). A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of Claim 1.